{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:32:06Z","timestamp":1788877926674,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11060-025-05268-7","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T12:22:26Z","timestamp":1760444546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rapid early progression of glioblastoma: evaluation of a novel prognostic radiologic biomarker"],"prefix":"10.1007","volume":"176","author":[{"given":"Jacob","family":"Guzzino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Crompton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhi","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Bogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujay A.","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Quinones-Hinojosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry C.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy J.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Laack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon H.","family":"Uhm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Ruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugur T.","family":"Sener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Breen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9150-2916","authenticated-orcid":false,"given":"Daniel M.","family":"Trifiletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"5268_CR1","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1186\/s12885-024-12469-2","volume":"24","author":"R Lakom\u00fd","year":"2024","unstructured":"Lakom\u00fd R, Lojov\u00e1 M, Souckova L et al (2024) 11\u00a0C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET). BMC Cancer 24:736. https:\/\/doi.org\/10.1186\/s12885-024-12469-2","journal-title":"BMC Cancer"},{"key":"5268_CR2","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.3390\/ijms24043521","volume":"24","author":"M Makowska","year":"2023","unstructured":"Makowska M, Smolarz B, Romanowicz H (2023) MicroRNAs (miRNAs) in glioblastoma multiforme (GBM)\u2014Recent literature review. IJMS 24:3521. https:\/\/doi.org\/10.3390\/ijms24043521","journal-title":"IJMS"},{"key":"5268_CR3","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.3390\/cancers15072116","volume":"15","author":"SSK Yalamarty","year":"2023","unstructured":"Yalamarty SSK, Filipczak N, Li X et al (2023) Mechanisms of resistance and current treatment options for glioblastoma multiforme (GBM). Cancers 15:2116. https:\/\/doi.org\/10.3390\/cancers15072116","journal-title":"Cancers"},{"key":"5268_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fnut.2018.00011","volume":"5","author":"KA Schwartz","year":"2018","unstructured":"Schwartz KA, Noel M, Nikolai M, Chang HT (2018) Investigating the ketogenic diet as treatment for primary aggressive brain cancer: challenges and lessons learned. Front Nutr 5:11. https:\/\/doi.org\/10.3389\/fnut.2018.00011","journal-title":"Front Nutr"},{"key":"5268_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/COC.0000000000000537","volume":"42","author":"JD Palmer","year":"2019","unstructured":"Palmer JD, Bhamidipati D, Shukla G et al (2019) Rapid early tumor progression is prognostic in glioblastoma patients. Am J Clin Oncol 42:481\u2013486. https:\/\/doi.org\/10.1097\/COC.0000000000000537","journal-title":"Am J Clin Oncol"},{"key":"5268_CR6","doi-asserted-by":"publisher","first-page":"5745","DOI":"10.1158\/1078-0432.CCR-16-2844","volume":"23","author":"BM Ellingson","year":"2017","unstructured":"Ellingson BM, Gerstner ER, Smits M et al (2017) Diffusion MRI phenotypes predict overall survival benefit from Anti-VEGF monotherapy in recurrent glioblastoma: converging evidence from phase II trials. Clin Cancer Res 23:5745\u20135756. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2844","journal-title":"Clin Cancer Res"},{"key":"5268_CR7","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A et al (2017) Effect of Tumor-Treating fields plus maintenance Temozolomide vs maintenance Temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA 318:2306. https:\/\/doi.org\/10.1001\/jama.2017.18718","journal-title":"JAMA"},{"key":"5268_CR8","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens A-C, Gorlia T et al (2005) MGMT gene Silencing and benefit from Temozolomide in glioblastoma. N Engl J Med 352:997\u20131003. https:\/\/doi.org\/10.1056\/NEJMoa043331","journal-title":"N Engl J Med"},{"key":"5268_CR9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s11060-017-2505-x","volume":"134","author":"CW Wee","year":"2017","unstructured":"Wee CW, Kim E, Kim TM et al (2017) Impact of interim progression during the surgery-to-radiotherapy interval and its predictors in glioblastoma treated with temozolomide-based radiochemotherapy. J Neurooncol 134:169\u2013175. https:\/\/doi.org\/10.1007\/s11060-017-2505-x","journal-title":"J Neurooncol"},{"key":"5268_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11060-016-2362-z","volume":"132","author":"A Merkel","year":"2017","unstructured":"Merkel A, Soeldner D, Wendl C et al (2017) Early postoperative tumor progression predicts clinical outcome in glioblastoma\u2014implication for clinical trials. J Neurooncol 132:249\u2013254. https:\/\/doi.org\/10.1007\/s11060-016-2362-z","journal-title":"J Neurooncol"},{"key":"5268_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11060-017-2511-z","volume":"134","author":"JE Villanueva-Meyer","year":"2017","unstructured":"Villanueva-Meyer JE, Han SJ, Cha S, Butowski NA (2017) Early tumor growth between initial resection and radiotherapy of glioblastoma: incidence and impact on clinical outcomes. J Neurooncol 134:213\u2013219. https:\/\/doi.org\/10.1007\/s11060-017-2511-z","journal-title":"J Neurooncol"},{"issue":"11","key":"5268_CR12","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jamaoncol.2016.1373","volume":"2","author":"TJ Brown","year":"2016","unstructured":"Brown TJ, Brennan MC, Li M et al (2016) Association of the extent of resection with survival in glioblastoma: A systematic review and Meta-analysis. JAMA Oncol 2(11):1460\u20131469. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1373","journal-title":"JAMA Oncol"},{"key":"5268_CR13","doi-asserted-by":"publisher","first-page":"vdac075","DOI":"10.1093\/noajnl\/vdac075","volume":"4","author":"M Waqar","year":"2022","unstructured":"Waqar M, Roncaroli F, Lehrer EJ et al (2022) Rapid early progression (REP) of glioblastoma is an independent negative prognostic factor: results from a systematic review and meta-analysis. Neurooncol Adv 4:vdac075. https:\/\/doi.org\/10.1093\/noajnl\/vdac075","journal-title":"Neurooncol Adv"},{"key":"5268_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ijrobp.2023.03.062","volume":"117","author":"DM Trifiletti","year":"2023","unstructured":"Trifiletti DM, Milano MT, Redmond KJ et al (2023) Treatment planning expansions in glioblastoma: how less can be more. Int J Radiation Oncology*Biology*Physics 117:293\u2013296. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.03.062","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"5268_CR15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.prro.2016.03.007","volume":"6","author":"AR Cabrera","year":"2016","unstructured":"Cabrera AR, Kirkpatrick JP, Fiveash JB et al (2016) Radiation therapy for glioblastoma: executive summary of an American society for radiation oncology Evidence-Based clinical practice guideline. Practical Radiation Oncol 6:217\u2013225. https:\/\/doi.org\/10.1016\/j.prro.2016.03.007","journal-title":"Practical Radiation Oncol"},{"key":"5268_CR16","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.3390\/cells12121639","volume":"12","author":"K Zappe","year":"2023","unstructured":"Zappe K, P\u00fchringer K, Pflug S et al (2023) Association between MGMT enhancer methylation and MGMT promoter methylation, MGMT protein Expression, and overall survival in glioblastoma. Cells 12:1639. https:\/\/doi.org\/10.3390\/cells12121639","journal-title":"Cells"},{"key":"5268_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.20892\/j.issn.2095-3941.2020.0179","volume":"18","author":"R Chai","year":"2021","unstructured":"Chai R, Li G, Liu Y et al (2021) Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma. Cancer Biol Med 18:271\u2013282. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2020.0179","journal-title":"Cancer Biol Med"},{"issue":"5","key":"5268_CR18","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/neuonc\/noac193","volume":"25","author":"P Karschnia","year":"2023","unstructured":"Karschnia P, Young JS, Dono A et al (2023) Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group. Neuro Oncol 25(5):940\u2013954. https:\/\/doi.org\/10.1093\/neuonc\/noac193PMID: 35961053; PMCID: PMC10158281","journal-title":"Neuro Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05268-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05268-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05268-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:34:04Z","timestamp":1767702844000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05268-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5268"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05268-7","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"5 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This was a retrospective observational study. The study was reviewed by the Mayo Clinic Institutional Review Board prior to its initiation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Dr. Trifiletti reports clinical trial research support from Novocure, Blue Earth Diagnostics Ltd., publishing fees from Springer Inc., consulting fees from Boston Scientific Corporation, Sevier Pharmaceuticals, and AFX Medical outside of submitted work, and is an editorial board member for the Journal of Neuro-oncology.Dr. Breen reports clinical trial research support from Wayshine Biopharma, and consulting\/scientific advisory funds paid to the institution from GE Healthcare and Miltenyi Biotec. Dr. Brown reports contributing to UpToDate, outside subject matter, receiving honorarium.Dr. Burns reports clinical trial research support from Predicine Inc, Aminex Therapeutics, Insightec, Abbvie Inc, Natus Medical Inc and SonALAsense as well as consulting fees from Boehringer Ingelheim and Servier pharmaceuticals. None of these are relevant to the current manuscript. None of the other authors have relevant conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}